Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PMA (premarket approval) review times continue to fall in the US

This article was originally published in Clinica

Executive Summary

The FDA has reduced further the time it takes to process applications to market medical devices in the US. In fiscal year 1998, which ended on September 31, the average review time for premarket approval applications (PMAs) from submission to approval fell to 12.4 months, a substantial 25% reduction on the 16.6 month average in 1997 and 50% less than the average of 25.9 months in 1996.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts